Table 1 The ratio of animals with clinical signs and the mortality after different treatment
From: Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles
Compound | Dose (mg/kg.bw) SLN/Tilmicosin | Animal number (Male/Female) | Animals with clinical sign/treated animals | Died animals/treated animals | ||
|---|---|---|---|---|---|---|
| Â | Â | Â | Male | Female | Male | Female |
Til-HCO-SLN | 5000/540 | 5/5 | 5/5 | 5/5 | 0/5 | 0/5 |
Til-HCO-SLN* | 766/75 | 5/5 | 0/5ab | 0/5ab | 0/5ab | 0/5ab |
HCO-SLN | 5000/0 | 5/5 | 5/5 | 5/5 | 0/5 | 0/5 |
HCO-SLN* | 766/0 | 5/5 | 0/5ab | 0/5ab | 0/5ab | 0/5ab |
Tilmicosin | -/540 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
Tilmicosin* | -/75 | 5/5 | 5/5a, 3/3b | 5/5a, 4/4b | 2/5a, 1/3b | 1/5a, 1/4b |
Saline | -/- | 5/5 | 0/5 | 0/5 | 0/5 | 0/5 |
Saline* | -/- | 5/5 | 0/5ab | 0/5ab | 0/5ab | 0/5ab |